Abstract
Late-Onset Neonatal Sepsis (LOS) is a rare, but life-threatening condition, involving widespread infection, immune disruption, organ dysfunction, and often death. Because exposure to pathogens is not 100% preventable, identifying susceptibility factors is critical to defining neonates at greater risk. Prior studies demonstrated that both genetics and infant sex influence susceptibility. We, therefore, performed a genome wide association study (GWAS) with 224 cases and 273 controls from six European countries to identify genetic risk factors. We tested for association with both autosomal and X-chromosome variants in the total sample and in the samples stratified by sex. In total 71 SNPs associated with neonatal sepsis at p<1×10−4 in at least one analysis. Most importantly, the sex stratified analyses revealed associations with multiple SNPs (28 SNPs in males and 16 in females), but none of 44 SNPs from single-sex analyses associated with sepsis in the other sex at p<0.05, and the vast majority showed significant SNP X sex interactions (17 of 28 from the male-only analyses and all 16 from the female-only study). Pathway analyses showed that NOTCH signaling is over-represented among loci identified by the analyses. Our results indicate that susceptibility to LOS is genetically sexually dimorphic, and suggest that NOTCH signaling is likely to play a role in it.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the European Commission under the FP7 (ID: 242146).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NeoMero study was the source of the case data and it was approved by the Ethics Review Committee University of Tartu (205T-18). Principal Investigators: Ursula Trafojer - Clinica Pediatrica, Padova, and Irja Lutsar - University of Tartu, Estonia, Study Chair: Jean-Pierre Aboulker Institut National de la Sante Etde la Recherche Medicale, France. Controls were randomly selected from existing DNA banks in 3 of the European countries: Greece, Italy, and Spain. All control samples were de-identified. Lutsar I, Trafojer UM, Heath PT, et al. Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial. Trials 2011;12:215. doi: 10.1186/1745-6215-12-215 [published Online First: 2011/10/01] Germovsek E, Lutsar I, Kipper K, et al. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. The Journal of antimicrobial chemotherapy 2018;73(7):1908-16. doi: 10.1093/jac/dky128 [published Online First: 2018/04/24] Lutsar I, Chazallon C, Trafojer U, et al. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. PloS one 2020;15(3):e0229380. doi: 10.1371/journal.pone.0229380 [published Online First: 2020/03/05] Corte-Real HB, Macaulay VA, Richards MB, et al. Genetic diversity in the Iberian Peninsula determined from mitochondrial sequence analysis. Ann Hum Genet 1996;60(4):331-50. doi: 10.1111/j.1469-1809.1996.tb01196.x [published Online First: 1996/07/01] Raveane A, Aneli S, Montinaro F, et al. Population structure of modern-day Italians reveals patterns of ancient and archaic ancestries in Southern Europe. Sci Adv 2019;5(9):eaaw3492. doi: 10.1126/sciadv.aaw3492 [published Online First: 2019/09/14]
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is not generally available due to ethical considerations but may be requested from the authors.
